BIOTEC Pharmacon SBG-2-03 : Essai de phase 3 randomisé, en double aveugle avec placebo, évaluant l’efficacité et la tolérance du SBG (Soluble béta-1,3/1,6 glucan), pour traiter les mucites orales, chez des patients ayant un cancer de la tête et du cou traités par radiothérapie. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions] L’objectif de cet essai est d’évaluer l’efficacité et la tolérance du béta-1,3/1,6 glucan sur la prévention de mucosite orale induite par la radiothérapie, chez des patients ayant un cancer de la tête...

• Country France
• organs Tête et cou
• Specialty Autres (cryothérapie, radiofréquence, homéopathie,...)

A randomised, double-blind, placebo-controlled study to determine the efficacy of soluble beta-1,3/1,6-glucan in chronic foot ulcers in diabetes To determine the effect of topically administered soluble beta-1,3/1,6-glucan (SBG) compared with that of placebo in chronic foot ulcers in diabetes.

• Country None
• organs None
• Specialty None

A randomised, double-blind, placebo-controlled study to assess the efficacy and safety of soluble beta-1,3/1,6-glucan (SBG) in chronic foot ulcers in patients with diabetes To compare the proportion of patients who have healing of their target ulcer within 8 weeks after starting topical treatment with SBG or placebo.

• Country None
• organs None
• Specialty None

A randomized, double-blind, placebo-controlled, parallel-group phase III clinical study to assess the efficacy and safety of soluble beta 1,3/1,6 glucan (SBG) on oral mucositis in head and neck cancer patients undergoing radiation therapy with or without chemotherapy To evaluate the efficacy and safety of SBG when administered from 1 day prior to 5 days after completion of radiotherapy.

• Country None
• organs None
• Specialty None

A randomized, double-blind, placebo-controlled, parallel-group phase III clinical study to assess the efficacy and safety of soluble beta 1,3/1,6 glucan (SBG) on oral mucositis in head and neck cancer patients undergoing radiation therapy with or without chemotherapy To evaluate the efficacy and safety of SBG when administered from 1 day prior to 5 days after completion of radiotherapy.

• Country None
• organs None
• Specialty None

A phase I/II study to assess the effect of soluble beta-1,3/1,6-glucan in combination with standard therapy in patients with breast cancer Define the clinical toxicity and assess the biologic effects of oral SBG when given to breast cancer patients undergoing standard chemo- and antibody treatment

• Country None
• organs None
• Specialty None